Brokerages expect Becton Dickinson and Co (NYSE:BDX) to announce $4.36 billion in sales for the current fiscal quarter, according to Zacks Investment Research. Nine analysts have issued estimates for Becton Dickinson and’s earnings, with estimates ranging from $4.29 billion to $4.46 billion. Becton Dickinson and reported sales of $4.28 billion in the same quarter last year, which indicates a positive year over year growth rate of 1.9%. The company is scheduled to announce its next quarterly earnings report on Thursday, August 1st.

On average, analysts expect that Becton Dickinson and will report full-year sales of $17.31 billion for the current fiscal year, with estimates ranging from $17.25 billion to $17.38 billion. For the next financial year, analysts anticipate that the firm will post sales of $18.19 billion, with estimates ranging from $18.11 billion to $18.31 billion. Zacks’ sales averages are a mean average based on a survey of research firms that that provide coverage for Becton Dickinson and.

Becton Dickinson and (NYSE:BDX) last posted its quarterly earnings data on Thursday, May 9th. The medical instruments supplier reported $2.59 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.57 by $0.02. The business had revenue of $4.20 billion for the quarter, compared to analysts’ expectations of $4.25 billion. Becton Dickinson and had a return on equity of 14.58% and a net margin of 5.88%. The business’s revenue was down .6% on a year-over-year basis. During the same period in the previous year, the firm posted $2.65 EPS.

Several analysts have weighed in on BDX shares. Raymond James cut their price objective on Becton Dickinson and from $290.00 to $280.00 and set a “strong-buy” rating on the stock in a research report on Tuesday, March 19th. TheStreet raised Becton Dickinson and from a “c+” rating to an “a” rating in a research report on Tuesday, February 5th. Zacks Investment Research cut Becton Dickinson and from a “hold” rating to a “sell” rating in a research report on Tuesday, April 16th. BMO Capital Markets dropped their price target on Becton Dickinson and from $272.00 to $270.00 and set a “market perform” rating on the stock in a research report on Friday, May 10th. Finally, KeyCorp reissued an “overweight” rating and issued a $262.00 price target (down from $273.00) on shares of Becton Dickinson and in a research report on Friday, May 10th. Six investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $255.31.

In related news, EVP Betty D. Larson sold 1,700 shares of the business’s stock in a transaction that occurred on Monday, May 13th. The shares were sold at an average price of $224.97, for a total value of $382,449.00. Following the completion of the transaction, the executive vice president now directly owns 11,493 shares in the company, valued at approximately $2,585,580.21. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Catherine M. Burzik acquired 285 shares of the firm’s stock in a transaction that occurred on Saturday, April 13th. The stock was purchased at an average price of $225.89 per share, with a total value of $64,378.65. The disclosure for this purchase can be found here. Over the last three months, insiders sold 28,198 shares of company stock worth $6,813,672. Insiders own 0.12% of the company’s stock.

A number of hedge funds and other institutional investors have recently made changes to their positions in BDX. Oregon Public Employees Retirement Fund raised its holdings in Becton Dickinson and by 22,485.4% in the 4th quarter. Oregon Public Employees Retirement Fund now owns 6,574,612 shares of the medical instruments supplier’s stock worth $29,000 after acquiring an additional 6,545,502 shares during the last quarter. Ronna Sue Cohen raised its holdings in Becton Dickinson and by 24,129.0% in the 1st quarter. Ronna Sue Cohen now owns 5,734,031 shares of the medical instruments supplier’s stock worth $5,734,000 after acquiring an additional 5,710,365 shares during the last quarter. Norges Bank purchased a new position in Becton Dickinson and in the 4th quarter worth approximately $515,703,000. FMR LLC raised its holdings in Becton Dickinson and by 5.0% in the 1st quarter. FMR LLC now owns 17,835,000 shares of the medical instruments supplier’s stock worth $4,453,934,000 after acquiring an additional 842,590 shares during the last quarter. Finally, Mackenzie Financial Corp raised its holdings in Becton Dickinson and by 27.7% in the 4th quarter. Mackenzie Financial Corp now owns 1,943,752 shares of the medical instruments supplier’s stock worth $437,966,000 after acquiring an additional 421,825 shares during the last quarter. Institutional investors own 84.57% of the company’s stock.

Becton Dickinson and stock opened at $235.22 on Wednesday. The company has a current ratio of 0.96, a quick ratio of 0.59 and a debt-to-equity ratio of 0.82. The company has a market cap of $62.97 billion, a price-to-earnings ratio of 21.36, a PEG ratio of 1.73 and a beta of 1.11. Becton Dickinson and has a fifty-two week low of $208.62 and a fifty-two week high of $265.87.

The business also recently declared a quarterly dividend, which will be paid on Friday, June 28th. Stockholders of record on Friday, June 7th will be given a $0.77 dividend. The ex-dividend date of this dividend is Thursday, June 6th. This represents a $3.08 dividend on an annualized basis and a dividend yield of 1.31%. Becton Dickinson and’s dividend payout ratio is currently 27.97%.

About Becton Dickinson and

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.

Recommended Story: What is a closed-end mutual fund (CEF)?

Get a free copy of the Zacks research report on Becton Dickinson and (BDX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.